Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.

T, Terui; S, Kobayashi; Y, Okubo; M, Murakami; K, Hirose; H, Kubo

doi:10.1001/jamadermatol.2017.5937

Public

Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.

Shared by NobleBlocks on Mar 1, 2018 • 12:00 AM UTC

Authors:

Terui T

Kobayashi S

Okubo Y

Abstract

<h4>Importance</h4>Palmoplantar pustulosis (PPP) is a recalcitrant skin disease with no biologics currently approved for treatment. The involvement of interleukin 23 (IL-23) and cytokines of the type 17 helper T cell lineage in the pathogenesis of PPP has been recently postulated.<h4>Objective</h4>T...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!